Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506
The freshly infused capital will primarily be deployed towards expansion and research & development
Nadda noted that TB treatment coverage in India has increased from 59% to 85%
The products will be manufactured in Goa India and marketed & distributed in Australian markets
Prior to joining Neuland, Deshmukh held several key positions at Cipla
The new site will increase Syngene's total single-use bioreactor capacity to 50,000L
Alkem Medtech to acquire 100% stake of Bombay Ortho
Empamore is poised to make a significant impact by offering high-quality treatment at an affordable price point, empowering millions of Indians to take control of their health
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Subscribe To Our Newsletter & Stay Updated
